Jeffry Weers is currently the Chief Technology Officer at cystetic Medicines, Inc. cystetic Medicines is focused on development of a novel genotype independent ion channel mimetic that restores anion transport in people with cystic fibrosis caused by Class 1 and other rare mutations for which there are currently no targeted therapies. He is a physical chemist with a Ph.D. in Chemistry from the University of California, Davis.
Jeff has spent the last 25 years of his career focused on the design of formulations and devices for respiratory drug delivery. In this regard he has worked for numerous companies including Alliance Pharmaceutical Corp., Inhale Therapeutic Systems (now Nektar Therapeutics), Transave, Inc. (now Insmed), Novartis Pharmaceutical Corp., and Respira Therapeutics.
Jeff has published more than 100 peer reviewed papers (h-index = 54), has authored several book chapters, and spoken at many national and international meetings. He is a prolific inventor with nearly 300 issued patents worldwide. Jeff’s inventions include a blood substitute (Oxygent™), an ultrasound contrast agent (Imagent®), a ventilation technique termed partial liquid ventilation (LiquiVent®), a hydrogel to prevent post-operative adhesions (FloGel®), and numerous patents related to engineered particles for inhalation (e.g., the PulmoSphere™ technology) which is utilized in inhaled drug products including TOBI® Podhaler™, Bevespi® Aerosphere, Breztri® Aerosphere and Ciprofloxacin DPI. Patents are also directed to aerosol delivery of antiinfectives utilizing combinations of liposome encapsulated and free drug (e.g., Arikayce®).
Jeff has received numerous awards including RDD’s Charles G. Thiel Award and the Alexander Fleming Serendipity Award from the London Business School. He is a Fellow of AAPS, an Associate Editor for Frontiers in Drug Delivery, and serves on the Editorial Board of the J Aerosol Med Pulm Drug Deliv.
